Merck & Co., Inc. said Monday that its Phase 3 TroFuse-005 trial for sacituzumab tirumotecan met its primary endpoints for endometrial cancer [1].

The results are significant because the drug targets advanced or recurrent endometrial cancer, a condition that often has limited treatment options for patients. By meeting dual endpoints of overall survival and progression-free survival, the trial suggests the therapy could provide a new standard of care for those with the disease [3].

Developed in collaboration with Kelun-Biotech, sacituzumab tirumotecan, or sac-TMT, is a TROP2-directed antibody-drug conjugate [1]. This class of medication is designed to deliver potent chemotherapy directly to cancer cells while sparing healthy tissue, a process intended to increase efficacy and reduce systemic toxicity [2].

The global study focused on patients who had already experienced advanced or recurrent forms of the malignancy [2]. The achievement of both overall survival and progression-free survival markers indicates that the drug not only delayed the growth of the cancer but also extended the lives of the participants [1].

This trial is part of a broader strategic partnership between the U.S.-based Merck and China-based Kelun-Biotech. The collaboration has seen significant regulatory momentum recently, securing four approvals in China over the last 18 months for the sac-TMT partnership [5].

Merck, known as MSD outside the U.S., continues to expand its oncology portfolio through these antibody-drug conjugates [1]. The company has not yet released the full detailed data set from the TroFuse-005 trial, but the meeting of primary endpoints typically serves as the basis for filing for regulatory approval with agencies like the U.S. Food and Drug Administration [3].

“The Phase 3 TroFuse-005 trial met its dual primary endpoints of overall survival and progression-free survival.”

The success of the TroFuse-005 trial positions sacituzumab tirumotecan as a potential heavyweight in the TROP2-directed therapy market. By proving efficacy in both survival and disease progression, Merck and Kelun-Biotech are moving toward a global regulatory submission that could challenge existing chemotherapy regimens for endometrial cancer, while further cementing the strategic pharmaceutical bridge between the U.S. and Chinese biotech sectors.